UB Paderborn / Katalog / Suche / in CDI

26 – 47 von 47

Sortiert nach

US Hemodialysis Facilities Switching from Cinacalcet to Etelcalcetide: Impact on Parathyroid Hormone (PTH) Levels: PO0546

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.208-209

2021

Volltextzugriff (PDF)

Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8603-TPS8603

2022

Volltextzugriff (PDF)

A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis

Clinical therapeutics, 2021-11, Vol.43 (11), p.2013-2023

2021

Volltextzugriff (PDF)

Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism

The journal of clinical endocrinology and metabolism, 2009-08, Vol.94 (8), p.2766-2772

2009

Volltextzugriff (PDF)

Efficacy of erenumab in chronic migraine patients with and without ictal allodynia

Cephalalgia, 2021-10, Vol.41 (11-12), p.1152-1160

2021

Volltextzugriff (PDF)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Cephalalgia, 2021-01, Vol.41 (1), p.6-16

2021

Volltextzugriff (PDF)

Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury

The FASEB journal, 2006-09, Vol.20 (11), p.1898-1900

2006

Volltextzugriff (PDF)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

Nephrology, dialysis, transplantation, 2020-09, Vol.35 (9), p.1642-1642

2020

Volltextzugriff (PDF)

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response

Cephalalgia, 2020-01, Vol.40 (1), p.28-38

2020

Volltextzugriff (PDF)

Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis

Headache, 2023-06, Vol.63 (6), p.730-742

2023

Volltextzugriff (PDF)

MO571PRACTICE PATTERNS ON THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN THE UNITED STATES: RESULTS FROM A MODIFIED DELPHI PANEL

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

Headache, 2022-05, Vol.62 (5), p.624-633

2022

Volltextzugriff (PDF)

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study

European journal of heart failure, 2018-02, Vol.20 (2), p.268-277

2018

Volltextzugriff (PDF)

Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real‐world clinical practice and outcomes

Hemodialysis international, 2022-04, Vol.26 (2), p.243-254

2022

Volltextzugriff (PDF)

SO030ONE YEAR EFFICACY AND SAFETY OF INTRAVENOUS (IV) ETELCALCETIDE (AMG 416) IN PATIENTS ON HEMODIALYSIS (HD) WITH SECONDARY HYPERPARATHYROIDISM (SHPT)

Nephrology, dialysis, transplantation, 2016-05, Vol.31 (suppl_1), p.i13-i14

2016

Volltextzugriff (PDF)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World EffectivenessPlain-Language Summary

Kidney medicine, 2022-06, Vol.4 (6), p.100475

2022

Volltextzugriff (PDF)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness

Kidney medicine, 2022-06, Vol.4 (6), p.100475-100475, Article 100475

2022

Volltextzugriff (PDF)

Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB

American journal of physiology. Heart and circulatory physiology, 2006-10, Vol.291 (4), p.H1838-H1846

2006

Volltextzugriff (PDF)

A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers

Biochemical journal, 2003-02, Vol.369 (Pt 3), p.485-496

2003

Volltextzugriff (PDF)

Abstract 15181: Predictors of Mortality and Morbidity in Patients With Chronic Heart Failure - Analysis of Red-HF Trial

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Erratum

Nephrology, dialysis, transplantation, 2019-05, p.1642-1642

2019

Volltextzugriff (PDF)

Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity

Endocrinology (Philadelphia), 2010-11, Vol.151 (11), p.5561-5562

2010

Volltextzugriff (PDF)

Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1)

Biochemical journal, 2002-09, Vol.366 (Pt 3), p.807-816

2002

Volltextzugriff (PDF)

26 – 47 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

US Hemodialysis Facilities Switching from Cinacalcet to Etelcalcetide: Impact on Parathyroid Hormone (PTH) Levels: PO0546

Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC)

A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis

Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism

Efficacy of erenumab in chronic migraine patients with and without ictal allodynia

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response

Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis

MO571PRACTICE PATTERNS ON THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN THE UNITED STATES: RESULTS FROM A MODIFIED DELPHI PANEL

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study

Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real‐world clinical practice and outcomes

SO030ONE YEAR EFFICACY AND SAFETY OF INTRAVENOUS (IV) ETELCALCETIDE (AMG 416) IN PATIENTS ON HEMODIALYSIS (HD) WITH SECONDARY HYPERPARATHYROIDISM (SHPT)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World EffectivenessPlain-Language Summary

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness

Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB

A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers

Abstract 15181: Predictors of Mortality and Morbidity in Patients With Chronic Heart Failure - Analysis of Red-HF Trial

Erratum

Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity

Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1)

Suchergebnisse filtern